Degeneration of the retinal ganglion cells (RGCs), their axons, and optic nerves (ONs) are hallmarks in glaucoma. Elevated intraocular pressure (IOP) is a risk factor for the development of primary open angle glaucoma (POAG) and current treatments for glaucoma are aimed at decreasing IOP. However, neuropathy is also observed in patients with normal tension glaucoma (IOP measurements of 6–10 mm Hg); suggesting that in addition to high IOP, there may be other common predisposing factors for the development of glaucoma. Therefore, other strategies for the treatment of glaucoma are needed, particularly those that improve or protect the health of RGCs and their axons.

The Sigma-1R (σ-1R) is a 26 kDa transmembrane, non-opioid receptor localized at the endoplasmic reticular (ER) membrane in some cells and at the nuclear envelope and ER in retinal cells. At the ER, the σ-1R complexes with the mitochondrion-associated ER membrane and regulates calcium transport and homeostasis between the two organelles. The mechanisms by which σ-1R modulate cell function are relatively unknown. However, recent observations suggest that the σ-1R associates with and prevents the influx of calcium by L-type voltage-gated calcium channels in RGCs. It has been suggested that the σ-1R provides a beneficial role in brain function. Earlier studies have suggested that σ-1R agonists are neuroprotective in Alzheimer’s disease, and serves as an effective antidepressant in mood disorders. In fact, the σ-1R also protect against β-amyloid exposure by inhibiting overexpression of the apoptotic protein, Bax, and TNF-related apoptosis inducing ligand (TRAIL) and phosphorylation of c-Jun N-terminal kinases (JNKs).

Studies in the retina have shown that mice lacking the σ-1R are more susceptible to injury and that there are substantial losses of RGCs in σ-1R-deficient mice exposed to retinal insults. There are accelerated RGC losses in diabetes/σ-1R knock out (K/O) mice and accelerated RGC losses in σ-1R K/O mice subjected to ONC. The significant neuroprotection of RGC from apoptosis was achieved by blocking the JNK/c-Jun pathway using either JNK inhibitor, SP600125.

Keywords: sigma 1 receptor, retina, optic nerve crush, pentazocine, retinal ganglion cells

Sigma-1R Protects Retinal Ganglion Cells in Optic Nerve Crush Model for Glaucoma

Linya Li, Shaoqing He, Yang Liu, Thomas Yorio, and Dorette Z. Ellis

1Department of Pharmaceutical Sciences, University of North Texas Systems College of Pharmacy, University of North Texas Health Science Center, Fort Worth, Texas, United States
2Department of Pharmacology and Neuroscience University of North Texas Health Science Center, Fort Worth, Texas, United States
3North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States

Correspondence: Dorette Ellis, Department of Pharmaceutical Sciences and North Texas Eye Research Institute, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, 76107 TX, USA; dorette.ellis@unthsc.edu.

Received: March 4, 2021
Accepted: May 28, 2021
Published: August 18, 2021
Citation: Li L, He S, Liu Y, Yorio T, Ellis DZ. Sigma-1R protects retinal ganglion cells in optic nerve crush model for glaucoma. Invest Ophthalmol Vis Sci. 2021;62(10):17. https://doi.org/10.1167/iovs.62.10.17

PURPOSE. The purpose of this study was to determine the effects of the Sigma-1R (σ-1R) on retinal ganglion cell (RGC) survival following optic nerve crush (ONC) and the signaling mechanism involved in the σ-1R protection.

METHODS. The overall strategy was to induce injury by ONC and mitigate RGC death by increasing σ-1R expression and/or activate σ-1R activity in σ-1R K/O mice and wild type (WT) mice. AAV2-σ-1R vector was used to increase σ-1R expression and σ-1R agonist used to activate the σ-1R and RGCs were counted. Immunohistochemical and Western blot analysis determined phosphorylated (p)-c-Jun, c-Jun, and Caspase-3. Pattern electroretinography (PERG) determined RGC activity.

RESULTS. RGC counts and function were similar in pentazocine-treated WT mice when compared to untreated mice and in WT mice when compared with σ-1R K/O mice. Pentazocine-induced effects and the effects of σ-1R K/O were only observable after ONC. ONC resulted in decreased RGC counts and activity in both WT and σ-1R K/O mice, with σ-1R K/O mice experiencing significant decreases compared with WT mice. The σ-1R transgenic expression resulted in increased RGC counts and activity following ONC. In WT mice, treatment with σ-1R agonist pentazocine resulted in increased RGC counts and increased activity when compared with untreated WT mice. There were time-dependent increases in c-Jun, p-c-Jun, and caspase-3 expression in ONC mice that were mitigated with pentazocine-treatment.

CONCLUSIONS. These findings suggest that the apoptotic pathway is involved in RGC losses seen in an ONC model. The σ-1R offers neuroprotection, as activation and/or transgenic expression of σ-1R attenuated the apoptotic pathway and restored RGCs number and function following ONC.

Keywords: sigma 1 receptor, retina, optic nerve crush, pentazocine, retinal ganglion cells.
or JNK2/3 deficient mice. Other studies indicate that ET-1-induced apoptosis in RGCs are associated with upregulation of c-Jun, Bax, therefore, investigating the role of c-Jun in the σ-1r-regulation of RGC function is critical to understand the working mechanism of the σ-1r. As with the brain, these observations suggest that the σ-1r confers neuroprotection in the retina. Therefore, we will test the hypothesis that the σ-1r is neuroprotective in the retina following optic nerve injury, using an in vivo model for acute retinal neurodegeneration, the ONC model, to determine the ability of the σ-1r to protect RGCs and the signaling pathway that may be involved.

**METHOD**

**Animals**

Mice were maintained under standard laboratory conditions (12/12 hours light/dark cycle and 20–24°C; and food and water were provided without restriction). The σ-1r-heterozygous mice (C-57BL) were crossed with wild-type (WT; C-57BL) or σ-1r-knock-out (K/O) mice. Research mice were bred in-house and their pups were genotyped by PCR before use in the experiments. All animal studies were conducted in the United States Department of Agriculture (USDA) and Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited animal facilities at the University of North Texas Health Science Center (UNTHSC) campus. All animals were treated in accordance with the principles described in the International Guiding Principles for Biomedical Research Involving Animals, the Association for Research in Vision and Ophthalmology, as well as all protocols and regulations established by the Institutional Animal Care and Use Committee of the UNTHSC.

**Optic Nerve Crush**

Optic nerve crush (ONC) was performed in σ-1r K/O mice and WT mice. Mice were anesthetized by intraperitoneal (IP) injection of ketamine and xylazine (100, 10 mg/kg, respectively). ONC was performed as previously described. Briefly, the left ON was exposed intra-orbitally through a small window made between the surrounding muscles. The ON was crushed approximately 1 mm behind the globe with self-closing forceps for 4 seconds under visualization. At end stages, the animals were euthanized by CO2 and the eyes were enucleated and RGCs counted as described below.

**RGC Counts**

RGCs were quantified by immunohistochemistry using the RNA-binding protein with multiple splicing antibodies (RBPMS antibodies) as described. Specifically, retinas were fixed, dissected, and flat-mounted and exposed to appropriate anti-RBPMS primary and secondary antibodies. Eight images 40 times the magnification were taken from peripheral and mid-peripheral regions around 4 quadrants of each retina and imported into Adobe Photoshop software. The number of cells presented in each retina was used as the average of these counts. The RGC density is expressed as the number of cells per mm². The cell count was performed in a masked manner. The RGCs were manually counted by two operators.

**RGC AAV2 Transduction**

Weeks two prior to ONC, mice were intravitreally (IVT) injected with AAV2-CAG-σ-1r-GFP (AAV2-σ-1r-GFP) vector (1.2 × 10^10) or AAV2-CAG-EGFP (AAV2 empty vector; 1.2 × 10^10).

**Pentazocine Treatment**

Pentazocine (+-PTZ 0.5 mg/kg; Sigma-Aldrich Corp., St. Louis, MO, USA), known to be neuroprotective, was injected intraperitoneally every other day for 1 week prior to ONC and after ONC.

**Western Blots**

Dissected retinas from enucleated eyes were homogenized in 120 ul of ice cold RIPA buffer containing 50 mM Tris, pH 7.4, 10 mM Mg²⁺, 1 mM EDTA, 1 mM EGTA, 10 mM benzamide, 0.08 mM sodium molybdate, 0.01% Triton X-100, 10 μM okadaic acid, 100 ng/mL leupeptin, 100 ng/mL aprotinin, and 2 mM sodium pyrophosphate and proteinase inhibitor (1:100). Protein concentration was determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). Samples were then electrophoresed on a pre-cast ready-made 12% SDS/PAGE gradient gel (Bio-Rad Laboratories). The protein was then transferred onto a PVDF membrane blot (Millipore, Billerica, MA, USA) overnight at 4°C. Membrane blots were then blocked with 4% non-fat dried milk for 1 hour (Bio-Rad Laboratories), and then probed with 1:1000 dilution of primary rabbit polyclonal antibody against sigma-1 receptor (Gift from Smith's laboratory) and c-Jun 1:1000 (cell signaling 9165S) overnight at 4°C. Membrane blots were then incubated at room temperature for 1 hour with a horseradish peroxidase conjugated secondary antibody (Bio-Rad Laboratories) at a dilution of 1:10000 in 4% non-fat dried milk. The proteins were visualized (Chemidoc XRS+ System with Image Lab Software; Bio-Rad Laboratories) using ECL detection reagent SuperSignal West Femto Maximum Sensitivity Substrate (Thermo, Rockford, IL, USA).

**Immunofluorescence**

Enucleated eyes were fixed and sectioned. Antigen retrieval was used and involved the use of 6 M urea in 0.1 M Tris pH 9.5 at 80°C for 10 minutes. Tissue sections were blocked with 5% normal donkey serum and 5% BSA + 0.1% Triton X-100 for 1 hour at room temperature and incubated with appropriate primary antibodies: affinity-purified σ-1r monoclonal antibody (1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or polyclonal antibody (1:100 dilution; Santa Cruz Biotechnology); RBPMS polyclonal antibody (1:100 dilution; GeneTex, Inc. Irvine, CA, USA), c-Jun (1:200, Cell Signaling #9165S), p-c-Jun (1:50, Santa Cruz sc-822), Caspase-3 (1:500, Cell Signaling #9664) at 4°C overnight. Coverslips were then washed three times with PBS, and a 1:1000 dilution of secondary antibodies donkey anti-rabbit or anti-mouse IgG (Alexa Fluor 647 or 488) conjugate and donkey anti-mouse IgG or anti-rabbit IgG (Alexa Fluor 546 conjugate Invitrogen, Carlsbad, CA, USA) were added and incubated for 1 hour in the dark at room temperature. After incubation, the coverslips were washed three times with PBS. Mounting was performed on glass slides using antifade reagent with DAPI (P36931 Prolong Gold; Invitrogen).
and allowed to dry for overnight in the dark. Tissues were imaged using a (LSM 510; Zeiss, Thornwood, NY, USA) at 40 times magnification.

**PERG Recording**

Pattern electroretinography (PERG) was performed with the JORVEC System (Intelligent Hearing Systems, Miami, FL, USA) by using binocular stimulation. Body temperature was monitored via a rectal thermometer and maintained at 37°C. A small drop of balanced saline was applied topically as necessary to prevent corneal dryness. The PERG signals were recorded from a subcutaneous stainless-steel needle (Grass, West Warwick, RI, USA) placed in the snout. The reference and ground electrodes were similar needles placed medially on the back of the head and at the root of the tail, respectively. The PERG was the average of three consecutive repetitions. The average PERG waveforms were analyzed automatically with MATLAB software (Math-Works) to identify the major positive (P1) and negative waves (N2), and to calculate the sum of their absolute values (peak-to-trough amplitude) electrode. Mice were weighed and anesthetized with an IP injection of ketamine/xylazine (100/10 mg/kg). Each mouse was placed on a thermostatically controlled heating pad during the recording.

**Statistical analysis** was performed using ANOVA, followed by Tukey's All Pairwise Multiple Comparison Test method for comparison of significant difference among different means.

**RESULTS**

**Effects of Pentazocine on RGC Density and Function are Observable Only After ONC Injury**

We tested the hypothesis that the σ-1r is activated in response to RGC stress induced by ONC. To test this hypothesis, in one set of experiments, 3-month-old WT mice were treated with and without pentazocine (0.5 mg/kg) and RGC numbers were counted and RGC activity measured by PERG. In another set of experiments, 3-month-old WT mice were treated with and without pentazocine (0.5 mg/kg) and subjected to ONC, and RGC numbers were counted and RGC activity measured by PERG. PBS served as controls for pentazocine-treatment and contralateral eyes that were not subjected to ONC served as controls for ONC treatment. Injection of pentazocine in σ-1r K/O animals served as control for off-receptor actions of pentazocine. In mice eyes that were not subjected to ONC, RGC numbers and PERG values are similar in both pentazocine-treated and PBS-treated mice (Figs. 1A, 1B). The WT mice were injected with pentazocine and then subjected to ONC, quantitative analysis demonstrated significant increases in RGC number in WT animals treated with pentazocine when compared with PBS-treated animals (Figs. 1C). Similarly, PERG of RGC activity was greater in pentazocine-treated mice subjected to ONC than in PBS-treated animals (Fig. 1D). Additionally, pentazocine failed to have a significant effect on RGC number in ONC-treated σ-1r K/O mice, when compared to non-pentazocine-treated animals, suggesting that the effects of pentazocine is occurring via the σ-1r (data not shown). Images of whole mount retinas provide qualitative evidence of decreased RGC density in mice subjected to ONC in the absence of pentazocine (Fig. 1E).

These data suggest that the effects of pentazocine on RGC function and numbers are observable only after ONC insults.

**The Effects of Knock-Out of the σ-1r on RGC Density and Function are Observable Only After ONC Injury**

To further test the hypothesis that the σ-1r is activated in response to injury, RGCs were quantified from whole mount retinas from 3-month-old WT mice and σ-1r K/O mice. Figure 2A demonstrates similar RGC density in both WT and σ-1r K/O mice. PERG confirms that retinal function is not compromised in σ-1r K/O mice (Fig. 2B). To assess the role of the σ-1r in RGCs in response to injury, both 3-month-old WT mice and σ-1r K/O mice were subjected to ONC. The contralateral eyes served as controls. Seven days post ONC resulted in significant decreases in RGC density in both WT and σ-1r K/O animals when compared with contralateral control, however, the losses in RGCs were greater in σ-1r K/O animals than in WT animals (Fig. 2C). PERG amplitude was significantly greater in ONC-treated WT mice when compared with σ-1r K/O mice subjected to ONC (Fig. 2D). Images of whole mount retinas provide qualitative evidence of decreased RGC density in σ-1r K/O mice subjected to ONC when compared with WT mice (Fig. 2E).

**Transfection and Expression of the σ-1r in RGCs in σ-1r K/O Mice**

To determine transfection efficiency, σ-1r K/O mice were intravitreally injected with AAV2-CAG-σ-1r-GFP and the transduction efficiency of the AAV2-CAG-σ-1r-GFP in RGCs was validated using RBPMS antibody and the σ-1r antibody. GFP staining in RGCs was validated previously. Figures 3A and 3C are immunohistochemical localization of the trans-β-1r in RGCs 2 weeks and 6 weeks post intravitreal injection, respectively. Co-localization of RBPMS antibody with σ-1r antibody demonstrate transfection in RGCs, DAPI staining validated RGC nuclei. Western blots (Figs. 3B and 3D) confirmed these findings; using the σ-1r antibody (σ-1r) we demonstrated that GFP/σ-1r fusion protein stained at molecular weight of 55 kDa, whereas there was no σ-1r staining in control or empty vector containing GFP. β-Tubulin served as loading controls.

**Expression of the σ-1r Restores RGCs After ONC**

To test if expression of the σ-1r in σ-1r K/O mice resulted in increased numbers of RGCs after exposure to ONC, K/O mice RGCs were transduced with AAV2-σ-1r-GFP or AAV2-empty vector for 2 weeks, and then exposed to ONC and animals were euthanized 7 days, 14 days, or 28 days post ONC. AAV2- empty vector served as control for AAV2-σ-1r-GFP and WT mice served as positive control. Quantitative assessment of RGCs demonstrated that there was a time-dependent decrease in RGC density after ONC exposure (Fig. 4A). However, RGC densities in wild type mice and AAV2-σ-1r-transduced σ-1r K/O mice were similar 7, 14, and 28 days post ONC (see Fig. 4A). RGC densities 14 days and 28 days post ONC were lower when compared with 7 days post ONC. As with RGC density post ONC, PERG demonstrated RGC function was similar in WT mice and AAV2-σ-1r-transduced σ-1r K/O mice 7 days post ONC (Fig. 4B).
FIGURE 1. The σ-1r is activated only after injury. (A, B) RGC cell count/density and function, as measured by pattern ERG (PERG) were similar in WT mice treated with PBS or with intraperitoneally injected pentazocine (PTZ; 0.5 mg/kg). RGC density is expressed as the number of cells per mm², counted in a masked manner. PERG of RGC is expressed as its measurement, amplitude (μV). There were six in each group for RGC density and PERG. (C, D) Wild-type mice (WT) were treated with PTZ and subjected to ONC (Crush). PTZ-treatment increased RGC density and function when compared with untreated animals suggesting that the σ-1r is only activated in response to injury. Data are shown as mean ± SEM. N = 6, each group for RGC density and PERG. ***Significantly different from control, P < 0.001, t-test), *significantly different from control, P < 0.05, t-test. (E) Flat mounts providing qualitative analysis of the density of RGCs of wild-type mice treated with PBS, PBS + ONC, pentazocine (PTZ) and PTZ + ONC that were quantified in A to 1D. Images were taken at 40 times magnification, scale bar = 50 μM.
FIGURE 2. The effects of σ-1r deficit on RGC density and function is manifested only after axonal injury. Wild-type (WT) and σ-1r K/O animals were subjected to ONC and RGC cells were counted and activity measured using PERG. (A, B) RGC density and function as measured PERG were similar in WT mice and σ-1r K/O. RGC density is expressed as the number of cells per mm², counted in a masked manner. PERG of RGC is expressed as amplitude (μV) measured. There were eight in each group for RGC density and PERG. (C, D) Wild-type mice (WT) and σ-1r K/O mice were subjected to ONC. RGC density and function were decreased in σ-1r K/O ONC-treated mice when compared with wild-type ONC-treated mice suggesting that the σ-1r is a stress response protein and is quiescence in physiological states. Data are shown as mean ± SEM, N = 8, each group for RGC density and PERG. ***Significantly different from σ-1r K/O ONC-treated mice, P < 0.001, t-test, *significantly different from σ-1r K/O ONC-treated mice, P < 0.05, t-test. (E) RGC flat mounts providing qualitative analysis of the density of RGCs of WT mice and σ-1r K/O mice exposed to ONC. Quantitative analysis was provided in A to D. Images were taken at 40 times magnification, scale bar = 50 μM.

Phosphorylated (p) c-Jun, c-Jun, and Caspase 3 are Upregulated in ONC

It had previously been determined that apoptotic proteins were upregulated in isolated primary RGCs in response to oxidative stress. Therefore, in these studies, we wanted to identify proteins that were involved in the ONC-induced response. We identified phosphorylated (p) c-Jun, c-Jun, and Caspase 3 in mouse RGCs. Immunohistochemical analysis determined that there was a time-dependent upregulation of...
Sigma-1R Protects RGCs in ONC Model

**FIGURE 3.** Transduction efficiency of the AAV2-σ-1r in RGCs was validated using RBPMS antibody (pink) for the detection of RGCs and the σ-1r antibody (red). Beta tubulin was used as loading control for Western blot analysis. (A, B) Immunostaining and Western blots for 2 weeks post AAV2 vector IVT delivery. Merged images demonstrate the transgenic expression of the σ-1r in RGCs. (C, D) Immunostaining and western blots for 6 weeks post AAV2 vector IVT delivery. Merged images demonstrate increased transgenic expression of the σ-1r in RGCs, Western blots validated this. A and C images were taken at 40 times magnification, scale bar = 50 μM. Representative of staining, N = 4.

Phosphorylated (p) c-Jun, c-Jun, and caspase 3 in response to ONC. Phosphorylated c-Jun and c-Jun were observed in RGCs 8 hours to 7 days post ONC (Fig. 5A). P-c-Jun was localized in the periphery and cytoplasm of the cells, whereas c-Jun was localized to the nucleus. In some instances, p-c-Jun co-localized with c-Jun. Contralateral control, without ONC, did not stain for either p-c-Jun or c-Jun. Most interestingly, caspase 3 expression was only observed 3 days and later post ONC (Fig. 5B).

**Activation of σ-1r Decreases c-Jun Expression**

To determine the effects of σ-1r on c-Jun expression, mice were injected with pentazocine and then subjected to ONC, contralateral eyes that were not subjected to ONC served as controls. Figures 6A and 6B Western blots and densitometric analysis, respectively, demonstrate that exposure of the animals to pentazocine resulted in decreased expression of c-Jun suggesting that the σ-1r mitigates the apoptotic pathway activated in response to ONC.

**DISCUSSION**

Degeneration of the ON is a crucial factor in many neurological dysfunctions, including glaucoma, diabetic retinopathy, optic neuritis, hereditary optic neuropathy, and mechanical injury of the optic nerve leading to losses of RGCs and eventually blindness. Using σ-1r K/O mice, we demonstrate for the first time that transgenic expression of the σ-1r protects RGCs and RGC function in animals exposed to ONC. We have demonstrated that the σ-1r protects RGCs by inhibition of the apoptotic pathway involving c-Jun, p-c-Jun and caspase 3 in a time-dependent manner.

In this study, two sets of experiments validated the role of the σ-1r as a stress response protein in retinal disease. Under physiological conditions, treatment with pentazocine in WT mice had no significant effect on RGC cell number and RGC function when compared to WT mice that were not treated with pentazocine. However, in WT mice, activation of the σ-1r by pentazocine followed by ONC resulted in increased RGC numbers and function when compared with untreated mice. Furthermore, in physiological conditions, RGC number and activity were similar in WT mice when compared with σ-1r K/O mice. However, after ONC there were decreased RGC numbers and RGC activity, however, RGC number and activity was greater in WT animals when compared with σ-1r K/O animals. These data confirm that the σ-1r is a stress response protein and is activated in response to injury, similar to that reported previously.3,11,25 Although no functional or morphological retinal deficits are observed in σ-1r K/O mice from birth to 6 months of age, there are qualitative changes in retinal function detected first in the optic nerve head, and as time progresses, in the ganglion cell layer by 12 months of age.5,26 It is currently accepted that aging allows for increased oxidative and cellular stresses, thus, absence of the σ-1r accelerates retinal dysfunction not seen in WT mice eyes. Additionally, increased IOP is associated...
FIGURE 4. Transgenic expression of the σ-1r restores RGC density and function up to 28 days following ONC. (A) There is significant exacerbation of RGC density loss following ONC in σ-1r K/O animals when compared to WT animals and compared with σ-1r K/O animals containing AAV2-σ-1r, demonstrating the ability of the σ-1r to attenuate RGC loss following injury. Although the density of RGCs decreased significantly 14 and 28 days post ONC, AAV2-σ-1r attenuated RGC loss following injury, similar to that of WT animals. Significantly different from σ-1r K/O and σ-1r K/O AAV2-empty vector. Data are shown as mean ± SEM N = 4, ***P < 0.001, **P < 0.01, *P < 0.05 ANOVA and Dunnett’s test. (B) Loss of RGC function was also exacerbated in σ-1r K/O animals following ONC when compared to WT animals and compared with σ-1r K/O animals containing AAV2-σ-1r. Data are shown as mean ± SEM n = 4* or #P < 0.05.

with RGC degeneration in glaucoma. Corroborative studies demonstrated that IOP was similar in 3 month old σ-1r K/O mice when compared with 3 month old WT mice. However, in response to induction of diabetes, IOP was increased in σ-1r K/O mice when compared with diabetic WT mice or non-diabetic WT mice. These observations, taken together, further validates the role of the σ-1r as a stress-response protein in retinal diseases.

There are several lines of evidence that demonstrate the protective role of the σ-1r in acute RGC degeneration in vivo. In WT mice, following ONC, there were significant decreases in RGCs in both pentazocine-treated and untreated mice when compared with non-ONC mice. However, the degree of RGC decrease is significantly greater in untreated animals when compared to pentazocine-treated animals. Additionally, when compared with mice lacking the σ-1r, RGC numbers in WT animals were significantly greater after ONC confirming the neuroprotective role of the σ-1r. Further evidence for the protective role of the σ-1r was demonstrated by the ability of transgenic expression of the σ-1r to restore RGC cell number and function to similar levels observed in WT mice. The significant decreases in RGC number in WT animals 7, 14, and 28 days post ONC, were observed, and these progressive decreases in RGC numbers result from the acute nature of the injury to the ON. Remarkably, transgenic expression of the σ-1r and activation of the σ-1r by pentazocine, slowed the losses of RGC cells, further demonstrating the protective effects of the σ-1r. These findings confirm our previous studies that determined that σ-1r is neuroprotective in primary RGC cultured cells that were exposed to oxidative stress.

In this study, the involvement of members of MAP kinase/c-JNK pathways, c-Jun, in σ-1r neuroprotection in RGCs were examined. Immunohistochemical analysis of c-Jun and p-c-Jun demonstrated time-dependent expressions, corroborating previously published observations.
Interestingly, the times of onset and duration of expression of c-Jun and p-c-Jun are not dependent on whether the insult to the tissue is chronic or acute. In acute injury by ONC, we tested and demonstrated p-c-Jun and c-Jun expression in RGCs at 8 hours to 7 days after ONC. Other studies demonstrated c-Jun expression after ONC between 195 days in rabbit retinal ganglion cell layer, and 6 hours after ONC in adult rats. In NMDA-induced neurodegenerative models, c-Jun and p-c-Jun expressions were observed 3 hours post NMDA-intravitreal injection in 8-week-old Wistar rats and was sustained up to 24 hours postinjection. In Sprague-Dawley rat retinas, p-c-Jun expression was increased 5 days post injected with NMDA, when compared with untreated retinas. In chronic models of IOP elevation that result in RGC losses, c-Jun and p-c-Jun levels were increased in RGCs on the first day after IOP increases and continued to 4 weeks after IOP increases. Using the Morrison glaucoma model in Brown Norway rats, it was demonstrated that there was an increased c-Jun expression 2 weeks post IOP elevation. Taken together, this suggests that p-c-Jun and c-Jun are early-to-intermediate response transcription factors.

Of interest, is that in RGCs, staining of anti-c-Jun and anti-p-c-Jun antibodies showed very little co-localization; as c-Jun expression was mostly in the nucleus, consistent with previous reports and p-c-Jun in the cytoplasm. Phosphorylation of c-Jun by JNK results in a more activated form p-c-Jun. Importantly, c-Jun and p-c-Jun have the ability to bind multiple targets forming complexes, thus regulating transcription and translation processes in multiple cell types.

Although the mechanisms by which c-Jun mediates the neurodegenerative processes after ONC remains unclear, previous studies demonstrated that inhibition of calcium...
channel lessened axonal and RGC degeneration and inhibited c-Jun and p-c-Jun expression.55 Inhibition of calcium channels also results in decreased JNK.56 These observations are of interest, as the σ-1R also associates with and prevents the influx of calcium by L-type voltage-gated calcium channels in RGCs,7 resulting in RGC protection. Additionally, activation of the σ-1R also results in decreased ONC-induced c-Jun and p-c-Jun expression. Taken together, this suggests that ONC-induced activation of the σ-1R results in decreased calcium influx, and decreased activation of the JNK/c-Jun/p- c-Jun pathway.

In our study, caspase 3 expression was not observed concurrently with c-Jun or p-c-Jun early expression, but was expressed three days after ONC, suggest a later response in the apoptotic pathway. Interestingly, pharmacological or molecular inhibition of the JNK/c-Jun pathway resulted in decreased caspase 3 expression suggesting up-stream regulation of caspase 3 by JNK and c-Jun.56 Additionally, activation of the σ-1R by pentazocine, known to be protective in retinal neurodegeneration, obliterates the ONC-induced expression of c-Jun, p-c-Jun, and caspase 3, corroborating previous results in primary RGCs. In our previous studies, activation of the σ-1R and overexpression of the σ-1R in isolated RGCs protected RGCs by inhibiting caspase 3/7 activity in primary RGCs subjected to OGD.31

Other members of the MAPK family are ERK1/2 and the p38 kinases. Previous studies in RGC primary cultures have demonstrated that in an oxygen glucose-deprived (OGD) model, activation of the σ-1R results in increased ERK1/2 phosphorylation, which correlates with increased numbers of RGCs, suggesting a neuroprotective role of increased ERK1/2 phosphorylation.52 Interestingly, other studies have demonstrated that in the RGC-supporting glial cells, σ-1R activation protects these cells from oxidative stress via modulation of ERK1/2 activity.53 Taken together, this suggests that the mechanisms by which the σ-1R confer protection on RGCs are complex, and may involve the MAPK/JNK/c-Jun/caspase 3 pathway, and possible other convergent pathways. Additionally, this current study explored the involvement of the MAPK/JNK/c-Jun/caspase 3 pathway in the pentazocine/σ-1R-induced neuroprotection of RGCs in an ONC model for retinal disease, however, these mechanisms may have relevance in other optic neuropathy involving RGC death, including diabetic retinopathy,5 but further studies are needed.

FIGURE 6. Activation of the σ-1R by pentazocine (PTZ) decreases c-Jun expression after ONC. WT mice that were treated with PTZ and exposed to ONC were stained with c-Jun and σ-1R antibodies. (A) Western blot and (B) densitometric analyses demonstrate that PTZ-induced activation of the σ-1R resulted in significant decreases in c-Jun expression following ONC. ***Significantly different from WT animals, and *significantly different from WT ONC-treated animals, N = 4. ***P < 0.001, *P < 0.05 ANOVA and Dunnett’s test.

Acknowledgments

Supported by University of North Texas Systems College of Pharmacy.

Disclosure: L. Li, None; S. He, None; Y. Liu, None; T. Yorio, None; D.Z. Ellis, None

References

1. Bahrami H. Causal inference in primary open angle glaucoma: specific discussion on intraocular pressure. *Opthalmic Epidemiol.* 2006;13(4):283–289.
2. Weng TY, Tsai SA, Su TP. Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases. *J Biomed Sci.* 2017;24(1):74.
3. Smith SB, Wang J, Cui X, Mysona BA, Zhao J, Bollinger KE. Sigma 1 receptor: A novel therapeutic target in retinal disease. *Prog Retin Eye Res.* 2018;67:130–149.
4. Mavlyutov TA, Epstein M, Guo LW. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. *Cell.* 2007;131(3):596–610.
5. Hayashi T, TP Su. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. *Cell.* 2007;131(3):596–610.
6. Hayashi T, Rizzuto R, Hajnoczky G, Su TP. MAM: more than just a housekeeper. *Trends Cell Biol.* 2009;19(2):81–88.
7. Mueller BH, Park Y, Daudt DR, III, et al. Sigma-1 receptor stimulation attenuates calcium influx through activated L-type voltage gated calcium channels in purified retinal ganglion cells. *Exp Eye Res.* 2013;107:21–31.
8. Maurice T, Su TP. The pharmacology of sigma-1 receptors. *Pharmacol Ther.* 2009;124:195–206.
9. Marrazzo A, Caraci F, Salinaro ET, Su TP, Copani A, Ronsivalle G. Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. *Neuroreport.* 2005 Aug 1;16(11):1223–1226.
10. Cantarella G, Buccolo C, Di BG, et al. Protective effects of the sigma agonist Pre-084 in the rat retina. *Br J Ophthalmol.* 2007;91:1382–1384.
11. Ha Y, Saul A, Tawfik A, Zorrilla EP, Ganapathy V, Smith SB. Diabetes accelerates retinal ganglion cell dysfunction in mice lacking sigma receptor 1. *Mol Vis.* 2012;18:2860–2870.
12. Mavlyutov TA, Nickells RW, Guo LW. Accelerated retinal ganglion cell death in mice deficient in the Sigma-1 receptor. *Mol Vis.* 2011;17:1034–1043.
Sigma-1R Protects RGCs in ONC Model

13. Kim BJ, Silverman SM, Liu Y, Wordinger RJ, Pang IH, Clark AF. In vitro and in vivo neuroprotective effects of c-Jun N-terminal kinase inhibitors on retinal ganglion cells. *Mol Neurodegener.* 2016;2111:30.

14. Sun H, Wang Y, Pang IH, et al. Protective effect of a JNK inhibitor against retinal ganglion cell loss induced by acute moderate ocular hypertension. *Mol Vis.* 2011;17:864–875.

15. Fernandes KA, Harder JM, Fornarola LB, et al. JNK2 and JNK3 are major regulators of axonal injury-induced retinal ganglion cell death. *Neurobiol Dis.* 2012;46(2):393–401.

16. He S, Park YH, Yorio T, Krishnamoorthy RR. Endothelin-mediated changes in gene expression in isolated purified rat retinal ganglion cells. *Invest Ophthalmol Vis Sci.* 2015;56(10):6144–6161.

17. Li Y, Schlamp CL, Nickells RW. Experimental induction of retinal ganglion cell death in adult mice. *Invest Ophthalmol Vis Sci.* 1999;40:1004–1008.

18. Kwong JMK, de Sevilla Müller LP, Brecha NC. The RNA binding protein RBPMS is a selective marker of ganglion cells in the mammalian retina. *J Comp Neurol.* 2014;522(6):1411–43.

19. Smith SB, Duplantier J, Dun Y, et al. In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine. *Invest Ophthalmol Vis Sci.* 2008;49(9):4154–4161.

20. Ellis DZ, Li L, Park Y, He S, Mueller B, Yorio T. Sigma-1 receptor regulates mitochondrial function in glucose- and oxygen-deprived retinal ganglion cells. *Invest Ophthalmol Vis Sci.* 2017;58(5):2755–2764.

21. Mueller BH, 2nd, Y Park, Ma HY, et al. Sigma-1 receptor stimulation protects retinal ganglion cells from ischemia-like insult through the activation of extracellular-signal-regulated kinases 1/2. *Exp Eye Res.* 2014;128:156–169.

22. Wang Y, Zhao S. Sigma-1 receptor activation ameliorates LPS-induced NO production and ROS formation through the Nrf2/HO-1 signaling pathway in cultured astrocytes. *Neurosci Lett.* 2019;711:134387.

23. Wang J, Shamugam A, Markand S, Zorrilla E, Ganapathy V, Smith SB. Sigma 1 receptor regulates the oxidative stress response in primary retinal Muller glial cells via Nrf2 signaling and system xc(-), the Na(+) independent glutamate-cystine exchanger. *Free Radic Biol Med.* 2015;86:25–36.

24. Delprat B, Crouzier L, Su TP, Maurice T. At the crossing of ER stress and MAMs: a key role of sigma-1 receptor? *Adv Exp Med Biol.* 2020;1131:699–718.

25. Ha Y, Sual A, Tawfik A, et al. Late-onset inner retinal dysfunction in mice lacking sigma receptor 1 (sigmaR1). *Invest Ophthalmol Vis Sci.* 2011;52(10):7749–7760.

26. Koistinaho J, Hicks JK, Sagar SM. Long-term induction of c-Jun mRNA and Jun protein in rabbit retinal ganglion cells following axotomy or colchicine treatment. *J Neurosci Res.* 1993;34(2):250–255.

27. Takeda M, Kato H, Takamiya A, Yoshida A, Kiyama H. Injury-specific expression of activating transcription factor-3 in retinal ganglion cells and its colocalized expression with phosphorylated c-Jun. *Invest Ophthalmol Vis Sci.* 2000;41(9):2412–2421.

28. Munemasa Y, Ohtani-Kaneko R, Kitaoka Y, et al. Pro-apoptotic role of c-Jun in NMDA-induced neurotoxicity in the rat retina. *J Neurosci Res.* 2006;83(5):907–918.

29. Zhang C, Wang Z, Zhao J, et al. Neuroprotective effect of lutein on NMDA-induced retinal ganglion cell injury in rat retina. *Cell Mol Neurobiol.* 2016;36:551–540.

30. Levkovitch-Verbin H, Quigley HA, Martin KR, et al. The transcription factor c-jun is activated in retinal ganglion cells in experimental rat glaucoma. *Exp Eye Res.* 2005;80(5):663–670.

31. He S, Minton AZ, Ma HY, Stankowska DL, Sun X, Krishnamoorthy RR. Involvement of AP-1 and C/EBPβ in upregulation of endothelin B (ETB) receptor expression in a rodent model of glaucoma. *PloS One.* 2013;8(11):e79183.

32. Liu H, Deng X, Shyu YJ, Li JJ, Taparowsky EJ, Hu CD. Mutual regulation of c-Jun and ATF2 by transcriptional activation and subcellular localization. *EMBO J.* 2006;25(5):1058–1069.

33. Nateri AS, Spencer-Dene B, Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. *Nature.* 2005;437(7056):281–285.

34. Ribas VT, Koch JC, Michel U, Bähr M, Lingor P. Attenuation of axonal degeneration by calcium channel inhibitors improves retinal ganglion cell survival and regeneration after optic nerve crush. *Mol Neurobiol.* 2017;54(1):72–86.

35. Song B, Xie B, Wang C, Li M. Caspase-3 is a target gene of c-Jun: ATF2 heterodimers during apoptosis induced by activity deprivation in cerebellar granule neurons. *Neurosci Lett.* 2011;505(2):76–81.

36. Zhao J, Mysona BA, Wang J, Gonsalvez GB, Smith SB, Bollinger KE. Sigma 1 receptor regulates ERK activation and promotes survival of optic nerve head astrocytes. *PLoS One.* 2017;12(9):e0184421.